- Home
- ANL vs GNTA Comparison
ANL vs GNTA Comparison
Compare ANL & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | GNTA |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | Cayman Islands | Italy |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.4M | 34.0M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANL | GNTA |
|---|---|---|
| Price | $7.34 | $0.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 210.3K | 53.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $0.71 |
| 52 Week High | $12.09 | $10.00 |
Technical Indicators
Market Signals| Indicator | ANL | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 38.98 |
| Support Level | $7.21 | $0.71 |
| Resistance Level | $9.98 | $1.70 |
| Average True Range (ATR) | 1.07 | 0.07 |
| MACD | -0.34 | 0.01 |
| Stochastic Oscillator | 11.90 | 12.67 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.